Advances in Hematology最新文献

{"title":"Factors Associated with Anemia among People Living with HIV/AIDS Taking ART in Ethiopia.","authors":"Ketema Bizuwork Gebremedhin,&nbsp;Tadesse Bedada Haye","doi":"10.1155/2019/9614205","DOIUrl":"https://doi.org/10.1155/2019/9614205","url":null,"abstract":"<p><strong>Background: </strong>Globally, anemia, among people living with HIV/AIDS, is a major public health problem. It has a significant effect on the progression of HIV/AIDS to advanced stages and there are a number of factors that often affect anemia. However, there is little insight regarding factors affecting anemia among HIV/AIDS patients in developing countries, including Ethiopia.</p><p><strong>Objective: </strong>This study aimed at investigating factors affecting anemia among people living with HIV/AIDS taking ART drug at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.</p><p><strong>Methods: </strong>A hospital based cross-sectional study design was used to assess factors affecting anemia among people living with HIV/AIDS. Structured checklist was used to gather information from charts of patients selected by simple random sampling method. We analyzed the data to identify factors associated with anemia among people with HIV/AIDS using logistic regression models.</p><p><strong>Results: </strong>A total of 301 selected charts were reviewed. The median age was 38 ± 10.38. The majority (62.5%) of the patients were taking ZDV-containing ART drug (ZDV/3TC/NVP). The overall anemia prevalence was 34.6%, while about 5%, 15.6%, and 14% of the patients had severe, moderate, and mild prevalence of anemia, respectively. Factors that were found to affect anemia among these patients include gender (OR = 2.26 [95% CI: 1.22, 4.16]), occupation (OR: 0.57 [95%CI: 0.35, 0.92]), WBC count (OR = 2.30 [95% CI: 1.29, 4.09]), platelet count (OR = 2.89 [95% CI: 0.99, 8.41]), nutritional status (OR = 2.05 [95% CI: 0.69, 6.02]), and WHO clinical stage of HIV/AIDS (OR = 3.69 [95% CI: 1.86, 7.31]).</p><p><strong>Conclusions: </strong>About one in three patients was found to be anemic. Intervention aimed at diagnosing and treating anemia among people living with HIV/AIDS should be considered.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2019 ","pages":"9614205"},"PeriodicalIF":0.0,"publicationDate":"2019-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/9614205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37114256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double-Blind Clinical Trial of Arginine Supplementation in the Treatment of Adult Patients with Sickle Cell Anaemia.","authors":"Renata M N Eleutério,&nbsp;Francisco O Nascimento,&nbsp;Tamara G Araújo,&nbsp;Marilena F Castro,&nbsp;Tarcísio P Almeida Filho,&nbsp;Pedro A Maia Filho,&nbsp;José Eleutério,&nbsp;Darcielle B D Elias,&nbsp;Romélia P G Lemes","doi":"10.1155/2019/4397150","DOIUrl":"https://doi.org/10.1155/2019/4397150","url":null,"abstract":"<p><strong>Background: </strong>Sickle cell anaemia (SCA) is the most prevalent monogenic disease in Brazil. In SCA, haemoglobin S (HbS) is formed, which modifies red blood cell morphology. Intravascular haemolysis occurs, in which free Hb and free radicals degrade nitric oxide (NO) and release arginase, which reduces arginine levels. Because arginine is a substrate for NO formation, this decrease leads to reduced NO (vasodilator) synthesis. SCA treatment uses hydroxyurea (HU) to maintain high foetal haemoglobin (HbF) levels and reduces HbS to avoid haemolytic episodes.</p><p><strong>Objective: </strong>To analyse the efficacy of L-arginine as an adjuvant in the treatment of SCA patients.</p><p><strong>Setting: </strong>The State Blood Centre of Ceará, Brazil.</p><p><strong>Methods: </strong>This was a randomized double-blind clinical study of adults with SCA with continuous use of HU at the State Blood Centre of Ceará. The clinical study enrolled 25 patients receiving HU + L-arginine (500 mg) and 25 patients receiving HU + placebo. The treatment was carried out over four months. Laboratory tests were performed to determine the levels of the following: (1) complete blood count; (2) nitrite + nitrate; (3) HbF; and (4) reticulocytes. The clinical experiments were performed by a haematologist. The main outcome measures were nitrite and pain.</p><p><strong>Results: </strong>Statistical analysis showed that the levels of NO were increased in the study group, and there was also a reduction in pain frequency using a pain frequency scale by day, week, and month. The levels of nitrite plus nitrate in the group receiving placebo plus HU did not change among the times evaluated (38.27 ± 17.27 mg/L, 39.49 ± 12.84 mg/L, 34.45 ± 11.25 mg/L, <i>p</i> >0.05), but in the patients who received supplementation with L-arginine plus HU, a significant increase in nitrite plus nitrate levels was observed between M0 and M4 (36.55 ± 20.23 mg/L versus 48.64 ± 20.63 mg/L, <i>p</i> =0.001) and M2 and M4 (35.71 ± 15.11 mg/L versus 48.64 ± 20.63 mg/L, <i>p</i> <0.001). It is important to note that the increase in nitrite plus nitrate levels occurred only in the fourth month of follow-up of patients in the treatment group, showing that at least 4 months of supplementation with L-arginine is necessary to show an increase in these metabolites in the serum.</p><p><strong>Conclusion: </strong>The use of L-arginine as a coadjuvant in the treatment of sickle cell anaemia may function as a potential tool for pain relief, consequently improving the life of patients.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2019 ","pages":"4397150"},"PeriodicalIF":0.0,"publicationDate":"2019-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/4397150","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37042318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France.","authors":"Huamao Mark Lin, Keith L Davis, James A Kaye, Katarina Luptakova, Saurabh P Nagar, Mohamad Mohty","doi":"10.1155/2019/4625787","DOIUrl":"10.1155/2019/4625787","url":null,"abstract":"<p><strong>Background: </strong>Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk.</p><p><strong>Methods: </strong>A retrospective medical record review was conducted in 200 RRMM patients in France. From first relapse, patients were assessed on second-/third-line treatments, progression-free survival (PFS), overall survival (OS), and healthcare utilization.</p><p><strong>Results: </strong>Fifty-five high risk and 113 standard risk patients were identified. Overall, 192 patients (96%) received second-line therapy after relapse. Lenalidomide-based regimens were most common (>50%) in second line. Hospitalization incidence in high risk patients was approximately twice that of standard risk patients. From Kaplan-Meier estimation, median (95% CI) second-line PFS was 21.4 (17.5, 25.0) months (by high versus standard risk: 10.6 [6.4, 17.0] versus 28.7 [22.1, 37.3] months). Among second-line recipients, 47.4% were deceased at data collection. Median second-line OS was 59.4 (38.8, NE) months (by high versus standard risk: 36.5 [17.4, 50.6] versus 73.6 [66.5, NE] months).</p><p><strong>Conclusions: </strong>The prognostic importance of cytogenetic risk in RRMM was apparent, whereby high (versus standard) risk patients had decidedly shorter PFS and OS. Frequent hospitalizations indicated potentially high costs associated with RRMM, particularly for high risk patients. These findings may inform economic evaluations of RRMM therapies.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2019 ","pages":"4625787"},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37026976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia.","authors":"Neetu Pandey,&nbsp;Geeta Yadav,&nbsp;Rashmi Kushwaha,&nbsp;Shailendra Prasad Verma,&nbsp;Uma Shankar Singh,&nbsp;Ashutosh Kumar,&nbsp;Prabhaker Mishra","doi":"10.1155/2019/1835091","DOIUrl":"https://doi.org/10.1155/2019/1835091","url":null,"abstract":"<p><strong>Background and objectives: </strong>Chronic myeloid leukemia (CML) is characterized by hyperproliferation of myeloid precursors, increased fibrosis, and neoangiogenesis in the bone marrow. Imatinib inhibits BCR-ABL tyrosine kinase produced due to reciprocal translocation t(9;22) in neoplastic CML cells. It reduces hyperproliferation of myeloid precursors and has been found to affect bone marrow fibrosis and angiogenesis. This study was done to assess the effect of imatinib on bone marrow morphology and angiogenesis in CML.</p><p><strong>Methods: </strong>31 newly diagnosed CML patients were evaluated before and after 3 months of imatinib therapy. A marrow morphological response (MMR) score was used to assess marrow cytological and histological features including grade of fibrosis. Mean microvessel density (MVD) was also assessed. Hematological parameters and BCR-ABL transcript levels were assessed in the peripheral blood.</p><p><strong>Results: </strong>86.21% of patients showed decrease in marrow cellularity with normalization of M:E ratio. 72.42% of patients had decrease in grade of fibrosis and 17.24% showed no change while 10.34% of patients showed progression of fibrosis grade. Patients with MMR score ≥ 2 (n=4) and those with progression of fibrosis grade (n=3) showed suboptimal molecular response (BCR-ABL transcripts > 10%). Pretherapy mean MVD of patients (14.69 ± 5.28) was higher than that of controls (6.32 ± 1.64). A significant reduction of 66.51% was observed in posttherapy mean MVD (4.98 ± 2.77) of CML patients (p<0.001).</p><p><strong>Conclusion: </strong>Imatinib therapy in CML not only decreases marrow cellularity, but also helps towards normalization of bone marrow microenvironment by reducing fibrosis and angiogenesis.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2019 ","pages":"1835091"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/1835091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36972990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso.","authors":"Salam Sawadogo,&nbsp;Koumpingnin Nebie,&nbsp;Tieba Millogo,&nbsp;Sonia Sontie,&nbsp;Ashmed Nana,&nbsp;Honorine Dahourou,&nbsp;Dieudonné Yentema Yonli,&nbsp;Jean-Baptiste Tapko,&nbsp;Jean-Claude Faber,&nbsp;Eléonore Kafando,&nbsp;Véronique Deneys","doi":"10.1155/2018/7938130","DOIUrl":"https://doi.org/10.1155/2018/7938130","url":null,"abstract":"<p><p>Traceability is an essential tool for haemovigilance and transfusion safety. In Burkina Faso, the implementation of haemovigilance has been achieved as part of a pilot project from 2005 to 2009. Our study aims to evaluate the traceability of blood transfusions and reporting of adverse reactions over the 6-year postpilot phase. A cross-sectional study including all blood units ordered between 2010 and 2015 has been conducted in public and private health care facilities supplied with blood products by the transfusion center of Bobo-Dioulasso. The complete traceability was possible for 83.5% of blood units delivered. Adverse reactions were reported in 107 cases representing 2.1/1,000 blood units per annum. Transfusions of wrong blood to wrong patient were reported in 13 cases. Our study shows that the haemovigilance system in Burkina Faso must be improved. Healthcare workers have to be sensitized on how traceability and haemovigilance could impact the quality of care provided to patients.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2018 ","pages":"7938130"},"PeriodicalIF":0.0,"publicationDate":"2018-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/7938130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36877480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Sickle Cell Disease in Ghana: The Korle-Bu Experience.","authors":"Eugenia V Asare,&nbsp;Ivor Wilson,&nbsp;Amma A Benneh-Akwasi Kuma,&nbsp;Yvonne Dei-Adomakoh,&nbsp;Fredericka Sey,&nbsp;Edeghonghon Olayemi","doi":"10.1155/2018/6161270","DOIUrl":"https://doi.org/10.1155/2018/6161270","url":null,"abstract":"<p><p>In Africa, sickle cell disease (SCD) is a major public health problem with over 200,000 babies born per year. In Ghana, approximately 15,000 (2%) of Ghanaian newborns are diagnosed with SCD annually. A retrospective review of medical records of all SCD patients aged 13 years and above, who presented to the sickle cell clinic at Ghana Institute of Clinical Genetics (GICG), Korle-Bu, from 1st January 2013 to 31st December 2014, was carried out, using a data abstraction instrument to document their phenotypes, demographics, attendance/clinic visits, pattern of attendance, and common complications seen. During the period under review 5,451 patients were seen at the GICG, with 20,788 clinic visits. The phenotypes were HbSS (55.7%) and HbSC (39.6%) with other sickle cell phenotypes (4.7%). Out of the 20,788 clinic visits, outpatient visits were 15,802 (76%), and urgent care visits were 4,986 (24%), out of which 128 (2.6%) patients were admitted to the Teaching Hospital for further management of their acute complications. There were 904 patient referrals (out of 5,451 patients) for specialist care; the 3 specialties that had the most referrals were Obstetrics and Gynaecology (168 patients), Orthopaedics (150 patients), and Ophthalmology (143 patients). In 2014, complications seen at KBTH included 53 patients with avascular necrosis (AVN) and 61 patients with chronic leg ulcers. Our centre has a large number of patients living with sickle cell disease. From our experience, early recognition and referral of sickle cell related complications can reduce morbidity and mortality associated with this disease. A multidisciplinary approach to care of SCD patients is therefore important.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2018 ","pages":"6161270"},"PeriodicalIF":0.0,"publicationDate":"2018-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/6161270","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36842899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Approach for Objective Assessment of White Blood Cells Using Computational Vision Algorithms.","authors":"Cesar Mauricio Rodríguez Barrero,&nbsp;Lyle Alberto Romero Gabalan,&nbsp;Edgar Eduardo Roa Guerrero","doi":"10.1155/2018/4716370","DOIUrl":"https://doi.org/10.1155/2018/4716370","url":null,"abstract":"<p><p>In the field of medicine, the analysis of blood is one of the most important exams to determine the physiological state of a patient. In the analysis of the blood sample, an important process is the counting and classification of white blood cells, which is done manually, being an exhaustive, subjective, and error-prone activity due to the physical fatigue that generates the professional because it is a method that consumes long laxes of time. The purpose of the research was to develop a system to identify and classify blood cells, by the implementation of the networks of Gaussian radial base functions (RBFN) for the extraction of its nucleus and subsequently their classification through the morphological characteristics, its color, and the distance between objects. Finally, the results obtained with the validation through the coefficient of determination showed an overall accuracy of 97.9% in the classification of the white blood cells per individual, while the precision in the classification by type of cell evidenced results in 93.4% for lymphocytes, 97.37% for monocytes, 79.5% for neutrophils, 73.07% for eosinophils, and a 100% in basophils with respect to the professional. In this way, the proposed system becomes a reliable technological support that contributes to the improvement of the analysis for identification of blood cells and therefore would benefit the low-level hematology establishments as well as to the processes of research in the area of medicine.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2018 ","pages":"4716370"},"PeriodicalIF":0.0,"publicationDate":"2018-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4716370","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36761683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.","authors":"Nora Chokr, Rima Patel, Kapil Wattamwar, Samer Chokr","doi":"10.1155/2018/2458679","DOIUrl":"10.1155/2018/2458679","url":null,"abstract":"<p><p>Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Several immune mechanisms have been identified in MDS, suggesting that immune dysregulation might be at least partially implicated in its pathogenesis. This has led to rigorous investigations on the role of immunomodulatory drugs as potential treatment options. Epigenetic modification via immune check point inhibition, while well established as a treatment method for advanced solid tumors, is a new approach being considered in hematologic malignancies including high risk MDS. Several trials are looking at the efficacy of these agents in MDS, as frontline therapy and in relapse, both as monotherapy and in combination with other drugs. In this review, we explore the utility of immune checkpoint inhibitors in MDS and current research evaluating their efficacy.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2018 ","pages":"2458679"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36753792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory T Cells and Profile of FOXP3 Isoforms Expression in Peripheral Blood of Patients with Myelodysplastic Syndromes.","authors":"Galina A Dudina,&nbsp;Almira D Donetskova,&nbsp;Marina M Litvina,&nbsp;Alexander N Mitin,&nbsp;Tatiana A Mitina,&nbsp;Sergey A Polyakov","doi":"10.1155/2018/8487403","DOIUrl":"https://doi.org/10.1155/2018/8487403","url":null,"abstract":"<p><p>We have investigated the frequencies of regulatory T cells and the level of FOXP3 isoforms expression in peripheral blood of patients with myelodysplastic syndromes and found the significant reduction of regulatory T cells at all stages of the disease. At the same time in untreated patients, we observed the shift in the FOXP3 isoforms expression profile towards the full-length molecule possibly due to inflammation. Based on the already known information about the potentially higher functional activity of FOXP3 molecule lacking exon 2, we have also hypothesized that our finding may explain the high risk of autoimmune disorders in this disease.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2018 ","pages":"8487403"},"PeriodicalIF":0.0,"publicationDate":"2018-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/8487403","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36656997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D and Nonskeletal Complications among Egyptian Sickle Cell Disease Patients.","authors":"Mona Hamdy,&nbsp;Niveen Salama,&nbsp;Ghada Maher,&nbsp;Amira Elrefaee","doi":"10.1155/2018/3867283","DOIUrl":"10.1155/2018/3867283","url":null,"abstract":"<p><p>Lower levels of vitamin D have been documented in many patients with sickle cell disease (SCD), but data are still inconclusive regarding the association between vitamin D deficiency (VDD) and the occurrence or the severity of various SCD complications. Our study aimed to detect the prevalence of vitamin D deficiency among Egyptian patients with SCD and to associate it with the clinical course of the disease. We measured the level of 25-hydroxy vitamin D in 140 children (age from 4.3 to 15.5years), 80 patients with SCD and 60 controls using enzyme-linked immunosorbent assay. Vitamin D was deficient in 60% of SCD compared to 26.7% of controls. Severe VDD was significantly higher in SCD patients than controls. Patients were divided into 2 groups; Normal group (32 patients) and Deficient group (48 patients). There were statistically significant differences between the 2 groups regarding their age, height percentile, the presence of clinical jaundice, and osseous changes (P values 0.043, 0.024, 0.001, and 0.015, respectively). Hemoglobin and hematocrit values were significantly lower in Deficient group (P values 0.022 and 0.004, respectively) while the levels of aspartate aminotransferase, lactate dehydrogenase, and total and indirect bilirubin were significantly higher in the same group (P values 0.006, 0.001, 0.038, and 0.016, respectively). The frequency of blood transfusions, hospitalization, and vasoocclusive crisis previous year as well as the history of bone fracture and recurrent infections proved to be significantly higher in Deficient group. These findings suggest that VDD may play a role in the pathogenesis of hemolysis and other complication of SCD. Vitamin D monitoring and supplementation in patients with SCD should be implemented as a standard of care to potentially improve health outcomes in these affected patients.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2018 ","pages":"3867283"},"PeriodicalIF":0.0,"publicationDate":"2018-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/3867283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36616213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}